Cargando…
P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
Autores principales: | Diaz-Tejedor, A., San-Segundo, L., Corchete, L. A., González-Méndez, L., Martín-Sánchez, M., Lorenzo-Mohamed, M., González-Rodríguez, M., Cruz-Hernández, M., Sánchez-Blázquez, M., Gutiérrez, N. C., Mateos, M.-V., Garayoa, M., Ocio, E. M., Paíno, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431353/ http://dx.doi.org/10.1097/01.HS9.0000846276.07813.d5 |
Ejemplares similares
-
Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, C., et al.
Publicado: (2018) -
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017) -
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2018) -
Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models
por: Qiu, Yushi, et al.
Publicado: (2018) -
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)